Biogen scientists are using green chemistry and other sustainable production methods to make medicines more efficiently, using less resources and energy.
Submitted by Biogen
How can sustainable manufacturing impact the environment? Biogen’s manufacturing group finds ways to reduce, reuse and recycle throughout the creation of a new medicine.
The world we know is threatened by pollution, loss of biodiversity, and a lack of resources - according to the American Chemical Society, an estimated 44 elements will face supply limitations in the coming years with some becoming challenging to access within 100 years.
Each one of us needs to do our part when it comes to taking care of the planet - reduce, reuse, recycle.
Individuals, private companies, communities, and countries can all have an impact.
Preserving the world's resources effect not only the health of the environment but the health of future generations.
At Biogen, we’re employing innovative, sustainable processes to actively reduce waste and minimize use of natural resources and energy.
These principles form the basis of green chemistry.
Producing a medicine involves the combination of a number of different ingredients across many steps; Biogen scientists are looking at the entire production process, finding ways to reduce the number of steps – creating new, more efficient, less wasteful, methods.
By using flow chemistry in our production process we are reducing the energy needed to reach the low temperatures required to create certain new medicines.
Beyond conserving energy, it's also about resources. Some of the ingredients that go into making a medicine are ubiquitous, while other ingredients are quite rare - so rare, in fact, that accessing them may become difficult in the next 50 years.
To conserve these resources, we utilize techniques that allow us to recycle and reprocess the elements needed in the production of medicines.
For example, we’ve initiated the use of packed-bed flow reactors to recover the catalyst in some reactions, allowing them to be reused after production completes.
These resources are finite - we must do our part to preserve them and the environment.
Biogen was the first company in the life sciences industry to become carbon neutral in 2014, and, by 2030, all of our products will achieve greater than 90% of our green chemistry targets - reducing waste at every step of the manufacturing process.
Still, we’re looking beyond even that – our aim is to go ‘beyond net zero’ – by way of our Healthy Climate, Healthy Lives initiative, a 20 year, 250 million dollar investment back into our planet to become fossil fuel free.
The changes that each of us make will shape our planet for future generations - Biogen is committed to this future. Join us as we strive toward building a stronger, more sustainable world for all.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.
More from Biogen